Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • DAPT (GSI-IX): Selective γ-Secretase Inhibitor for Notch ...

    2025-11-05

    DAPT (GSI-IX): Selective γ-Secretase Inhibitor for Notch Pathway Modulation

    Executive Summary: DAPT (GSI-IX) is a potent and orally bioavailable γ-secretase inhibitor (IC50 = 20 nM in HEK 293 cells) that selectively blocks the proteolytic processing of amyloid precursor protein (APP) and Notch receptors, reducing amyloid-β peptide generation (IC50 = 115 nM in cell-based assays) [ApexBio]. It is extensively used in Alzheimer's and cancer research to dissect Notch and amyloidogenic pathways (Wu et al., 2019). DAPT modulates cellular differentiation, autophagy, and apoptosis in diverse models. Formulated as a solid, it is soluble in DMSO and ethanol but insoluble in water, with strict storage requirements. In vivo, DAPT at 10 mg/kg/day reduces angiogenesis markers in Balb/C mice tumor models [ApexBio].

    Biological Rationale

    γ-Secretase is a multi-subunit protease complex crucial for cleaving type I transmembrane proteins, including APP and Notch receptors. Inhibition of γ-secretase activity blocks the release of β-amyloid peptides, a hallmark of Alzheimer's pathology (Wu et al., 2019). Notch signaling is central to cell fate determination, differentiation, and immune regulation. Aberrant Notch activation is implicated in oncogenesis, autoimmune disorders, and developmental anomalies. DAPT, as a selective γ-secretase inhibitor, enables researchers to specifically interrogate these pathways without broadly impacting other proteases. Its use in hepatobiliary organoid models demonstrates the utility of Notch modulation in tissue engineering and disease modeling (Wu et al., 2019).

    Mechanism of Action of DAPT (GSI-IX)

    DAPT (GSI-IX) inhibits γ-secretase by binding to its presenilin catalytic core, preventing cleavage of substrates such as APP and Notch. This causes reduced generation of amyloid-β peptides (Aβ40, Aβ42) and blocks Notch intracellular domain (NICD) formation, halting downstream gene transcription. In cell-based assays, DAPT achieves 50% inhibition of APP cleavage at 115 nM. In SHG-44 glioma cells, 1.0 μM DAPT inhibits proliferation via apoptosis induction. Inhibition of Notch signaling by DAPT alters differentiation dynamics in stem cell and cancer models, and in vivo administration reduces tumor angiogenesis marker expression [ApexBio]. The compound does not inhibit other protease families at relevant concentrations, supporting its selectivity profile.

    Evidence & Benchmarks

    • DAPT (GSI-IX) inhibits γ-secretase activity with an IC50 of 20 nM in HEK 293 cells (ApexBio).
    • Reduces amyloid-β (Aβ40, Aβ42) peptide generation in cell-based assays (IC50 = 115 nM) (ApexBio).
    • Suppresses Notch signaling, altering cell fate and differentiation in hiPSC-derived hepatobiliary organoids (Wu et al., 2019).
    • Inhibits SHG-44 glioma cell proliferation at 1.0 μM via apoptosis pathway activation (ApexBio).
    • In vivo, 10 mg/kg/day DAPT reduces tumor angiogenesis markers in Balb/C mice (ApexBio).
    • Does not require exogenous cells or genetic manipulation to modulate Notch in organoid systems (Wu et al., 2019).

    For additional mechanistic analysis and optimization strategies, see this article, which provides deeper insights into DAPT’s role in organoid modeling and advanced autoimmune applications. This present article extends those findings with updated benchmarks and workflow guidance.

    Applications, Limits & Misconceptions

    DAPT’s primary applications include:

    • Alzheimer's disease research—blocking amyloidogenic processing (ApexBio).
    • Cancer research—modulating Notch-dependent tumorigenesis and angiogenesis (DAPT Strategic Disruption). The present article updates mechanistic context and parameterization for solid tumor models.
    • Immune regulation and autoimmune disorder modeling via Notch pathway inhibition.
    • Organoid engineering—enabling selective lineage specification in hiPSC-derived hepatobiliary models (Wu et al., 2019).

    DAPT also facilitates apoptosis assays and autophagy modulation studies. For advanced cell fate and regenerative pathway applications, see this review; the current article clarifies storage and dosing parameters in translational contexts.

    Common Pitfalls or Misconceptions

    • DAPT is not effective in inhibiting unrelated proteases (e.g., caspases, matrix metalloproteases) at recommended concentrations.
    • It does not reverse established amyloid plaques in vivo; it blocks new amyloid-β generation only.
    • Solubility is limited in aqueous buffers; DMSO or ethanol (with ultrasound) are required for stock preparation.
    • Long-term storage of DAPT solutions (> several months) can lead to loss of potency, especially above -20°C.
    • Notch-independent cellular phenotypes are not affected by DAPT, limiting its use to γ-secretase/Notch-dependent models.

    Workflow Integration & Parameters

    DAPT (GSI-IX) is supplied as a solid (molecular weight: 432.46 g/mol). Prepare stock solutions at ≥21.62 mg/mL in DMSO or ≥16.36 mg/mL in ethanol (ultrasonic assistance recommended). Working concentrations commonly range from 0.1–10 μM, with 1.0 μM effective for SHG-44 glioma cells in vitro. For in vivo studies, administer 10 mg/kg/day subcutaneously in rodent models (ApexBio). Store powder at -20°C; stock solutions below -20°C for several months. Avoid repeated freeze-thaw cycles. Incorporate DAPT into cell culture or organoid induction protocols where Notch/APP cleavage is mechanistically relevant. For advanced troubleshooting in angiogenesis or regenerative models, see this resource; this article details updated storage and dosing constraints.

    Conclusion & Outlook

    DAPT (GSI-IX) remains a gold standard for γ-secretase inhibition, enabling reproducible interrogation of Notch and amyloidogenic pathways in diverse experimental systems. Its selectivity, potency, and compatibility with advanced organoid and in vivo models underpin its continued relevance for neurodegenerative, cancer, and immune research. Future applications may focus on combinatorial regimens and refined delivery for translational medicine. For detailed product specifications and ordering, visit the A8200 DAPT (GSI-IX) product page.